iNKT cells, specialized T lymphocytes that recognize glycolipid antigens via CD1d, normally contribute to cancer immune surveillance and can kill CRC cells through the perforin–granzyme pathway. This evidence concerns the gene PRF1 and colorectal carcinoma.